Overview

Efficacy and Safety of Zoledronic Acid in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Zoledronic acid is a medication that slows the breakdown of bone. This study will assess the efficacy and safety of zoledronic acid in Chinese patients with multiple myeloma or other solid tumors with bone metastases.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Diphosphonates
Zoledronic Acid